Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/17931
Title: | Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study | Authors: | CLAES, Nele DHAEZE, Tessa FRAUSSEN, Judith BROUX, Bieke VAN WIJMEERSCH, Bart STINISSEN, Piet HELLINGS, Niels SOMERS, Veerle Hupperts, Raymond |
Issue Date: | 2014 | Source: | PloS one, 9 (10), p. 1-8 | Abstract: | Background and objective: The long term effects of fingolimod, an oral treatment for relapsing-remitting (RR) multiple sclerosis (MS), on blood circulating B and T cell subtypes in MS patients are not completely understood. This study describes for the first time the longitudinal effects of fingolimod treatment on B and T cell subtypes. Furthermore, expression of surface molecules involved in antigen presentation and costimulation during fingolimod treatment are assessed in MS patients in a 12 month follow-up study. Methods: Using flow cytometry, B and T cell subtypes, and their expression of antigen presentation, costimulation and migration markers were measured during a 12 month follow-up in the peripheral blood of MS patients. Data of fingolimodtreated MS patients (n = 49) were compared to those from treatment-naive (n = 47) and interferon-treated (n = 27) MS patients. Results: In the B cell population, we observed a decrease in the proportion of non class-switched and class-switched memory B cells (p,0.001), both implicated in MS pathogenesis, while the proportion of naive B cells was increased during fingolimod treatment in the peripheral blood (PB) of MS patients (p,0.05). The remaining T cell population, in contrast, showed elevated proportions of memory conventional and regulatory T cells (p,0.01) and declined proportions of naive conventional and regulatory cells (p,0.05). These naive T cell subtypes are main drivers of MS pathogenesis. B cell expression of CD80 and CD86 and programmed death (PD) -1 expression on circulating follicular helper T cells was increased during fingolimod follow-up (p,0.05) pointing to a potentially compensatory mechanism of the remaining circulating lymphocyte subtypes that could provide additional help during normal immune responses. Conclusions: MS patients treated with fingolimod showed a change in PB lymphocyte subtype proportions and expression of functional molecules on T and B cells, suggesting an association with the therapeutic efficacy of fingolimod. | Notes: | Somers, V (reprint author),Hasselt Univ, Biomed Res Inst, Diepenbeek, Belgium veerle.somers@uhasselt.be | Document URI: | http://hdl.handle.net/1942/17931 | ISSN: | 1932-6203 | e-ISSN: | 1932-6203 | DOI: | 10.1371/journal.pone.0111115 | ISI #: | 000343943700063 | Rights: | © 2014 Claes et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2015 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
journal.pone.0111115.pdf | Published version | 771.96 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.